Diarrhea News and Research

Latest Diarrhea News and Research

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Study suggests potential new way to block cancer-causing gene

Study suggests potential new way to block cancer-causing gene

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

New combination treatment approved by FDA for metastatic pancreatic cancer

New combination treatment approved by FDA for metastatic pancreatic cancer

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Loyola gastroenterologist provides tips to IBS patients for healthy living

Loyola gastroenterologist provides tips to IBS patients for healthy living

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

AGS releases updated, expanded Beers Criteria to improve medication use in older adults

AGS releases updated, expanded Beers Criteria to improve medication use in older adults

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Invasive Salmonella infections revealed as major cause of child illness and deaths in Africa

Invasive Salmonella infections revealed as major cause of child illness and deaths in Africa

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.